Figure 5

The β-secretase inhibitor lanabecestat increases sleep at night in WT but not in appb^−/− mutants

(A and B) Exemplar 48 h traces on a 14h:10h light:dark cycle of the average waking activity of WT (A) and appb^−/− mutants (B) continuously exposed to either 0.3 μM lanabecestat or DMSO vehicle control.

(C and D) Exemplar 48 h traces of the average sleep from the same experiment shown in A and B.

(E) Night sleep and (F) night sleep bout length of WTs and appb^−/− mutants exposed to either 0.3 μM lanabecestat or DMSO vehicle. At top, each dot represents a single larva normalized to its experiment-matched WT (-lanabecestat) mean, and error bars indicate ±SEM. At bottom, the within-genotype effect size and 95%CIs of 0.3 μM lanabecestat treatment are plotted. n = the number of larvae. Data are pooled from N = 4 independent experiments, omitting the first day and night to account for any delay in drug action. ^nsp > 0.05, ∗p ≤ 0.05, ∗∗p ≤ 0.01, two-way ANOVA, Tukey’s post hoc test. n = number of larvae.